Skip to main content
Top
Published in: Cardiovascular Intervention and Therapeutics 2/2015

01-04-2015 | Case Report

Extremely late (7 years) paclitaxel-eluting stent thrombosis

Authors: J. A. Linares Vicente, J. R. Ruiz Arroyo, B. Simó Sánchez, A. Lukic, P. Revilla Martí

Published in: Cardiovascular Intervention and Therapeutics | Issue 2/2015

Login to get access

Excerpt

In the last decade percutaneous coronary interventions (PCI) with drug-eluting stents (DES) have reduced significantly restenosis rates. Therefore, DES have become the standard of care and most widely used for the treatment of atherosclerotic coronary artery disease [1]. Very late stent thrombosis (VLST), defined as stent thrombosis at the site of PCI 1 year after stent deployment by the Academic Research Consortium, has been recognized as a DES implantation complication [2]. It has been related to delayed arterial healing and positive vessel remodelling, leading to late-acquired stent malapposition and incomplete reendothelization [3, 4]. Second-generation DES are associated with lower rates of stent thrombosis [5], but VLST up to 5 years has been widely described in first-generation DES (sirolimus and paclitaxel DES) [68], and even extremely cases (7–8 years) have been communicated with sirolimus DES (SES) implantation after antiplatelet therapy cessation [9, 10]. Nevertheless, extremely VLST related to paclitaxel DES (PES), even on aspirin treatment, has not been previously described. This report presents a case of definite and extremely VLST 7 years after a PES deployment at culprit lesion for acute myocardial infarction (AMI). …
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Acad Res Consort Circulation. 2007;115(17):2344–51. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Acad Res Consort Circulation. 2007;115(17):2344–51.
3.
go back to reference Otsuka F, Nakano M, Ladich E, Kolodgie FD, Virmani R. Pathologic etiologies of late and very late stent thrombosis following first-generation drug-eluting stent placement. Thrombosis. 2012;2012:608593.CrossRefPubMedCentralPubMed Otsuka F, Nakano M, Ladich E, Kolodgie FD, Virmani R. Pathologic etiologies of late and very late stent thrombosis following first-generation drug-eluting stent placement. Thrombosis. 2012;2012:608593.CrossRefPubMedCentralPubMed
4.
go back to reference Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115(18):2426–34.CrossRefPubMed Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115(18):2426–34.CrossRefPubMed
5.
go back to reference De la Torre Hernández JM, Alfonso F, Gimeno F, Diarte JA, Lopez-Palop R, de Pérez Prado A, et al. Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2. JACC Cardiovasc Interv. 2010;3(9):909–11. De la Torre Hernández JM, Alfonso F, Gimeno F, Diarte JA, Lopez-Palop R, de Pérez Prado A, et al. Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2. JACC Cardiovasc Interv. 2010;3(9):909–11.
6.
go back to reference Schinkel AF, Barlis P, van Beusekom HM, Serruys PW, Regar E. Optical coherence tomography findings in very late (4 years) paclitaxel-eluting stent thrombosis. JACC Cardiovasc Interv. 2008;1(4):449–51.CrossRefPubMed Schinkel AF, Barlis P, van Beusekom HM, Serruys PW, Regar E. Optical coherence tomography findings in very late (4 years) paclitaxel-eluting stent thrombosis. JACC Cardiovasc Interv. 2008;1(4):449–51.CrossRefPubMed
7.
go back to reference Joyal D, Rudski L. Sirolimus-eluting stent thrombosis several years after clopidogrel discontinuation. J Invasive Cardiol. 2007;19(9):E265–7.PubMed Joyal D, Rudski L. Sirolimus-eluting stent thrombosis several years after clopidogrel discontinuation. J Invasive Cardiol. 2007;19(9):E265–7.PubMed
8.
go back to reference Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyakazi S, Muramatsu T, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher registry. Circulation. 2012;125(4):584–91.CrossRefPubMed Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyakazi S, Muramatsu T, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher registry. Circulation. 2012;125(4):584–91.CrossRefPubMed
9.
go back to reference Taylor-Sutton JE, Kim MC. Very late stent thrombosis approximately 7 years after deployment and one-week cessation of dual antiplatelet therapy. J Invasive Cardiol. 2011;23(12):E273–6.PubMed Taylor-Sutton JE, Kim MC. Very late stent thrombosis approximately 7 years after deployment and one-week cessation of dual antiplatelet therapy. J Invasive Cardiol. 2011;23(12):E273–6.PubMed
10.
go back to reference Spagnoli V, Veugeois A, Caussin C, Amabile N. Extremely late drug-eluting stent thrombosis related to uncovered struts: the phantom menace. Eur Heart J. 2013;34(31):2428.CrossRefPubMed Spagnoli V, Veugeois A, Caussin C, Amabile N. Extremely late drug-eluting stent thrombosis related to uncovered struts: the phantom menace. Eur Heart J. 2013;34(31):2428.CrossRefPubMed
11.
go back to reference Siddiqi OK, Faxon DP. Very late stent thrombosis: current concepts. Curr Opin Cardiol. 2012;27(6):634–41.CrossRefPubMed Siddiqi OK, Faxon DP. Very late stent thrombosis: current concepts. Curr Opin Cardiol. 2012;27(6):634–41.CrossRefPubMed
12.
go back to reference Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113(8):1108–13.CrossRefPubMed Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113(8):1108–13.CrossRefPubMed
13.
go back to reference Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126–30.CrossRefPubMed Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126–30.CrossRefPubMed
14.
go back to reference Lee CW, Kang SJ, Park DW, Lee SH, Kim YH, Kim JJ, et al. Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation. J Am Coll Cardiol. 2010;55(18):1936–42.CrossRefPubMed Lee CW, Kang SJ, Park DW, Lee SH, Kim YH, Kim JJ, et al. Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation. J Am Coll Cardiol. 2010;55(18):1936–42.CrossRefPubMed
15.
go back to reference Costa MA, Sabate M, Angiolillo DJ, Jimenez-Quevedo P, Teirstein P, Carter A, et al. Intravascular ultrasound characterization of the “black hole” phenomenon after drug-eluting stent implantation. Am J Cardiol. 2006;97(2):203–6.CrossRefPubMed Costa MA, Sabate M, Angiolillo DJ, Jimenez-Quevedo P, Teirstein P, Carter A, et al. Intravascular ultrasound characterization of the “black hole” phenomenon after drug-eluting stent implantation. Am J Cardiol. 2006;97(2):203–6.CrossRefPubMed
16.
go back to reference Zhang T, Shen L, Hu L, He B. Optimal duration of dual-antiplatelet therapy following drug-eluting stent implantation: a meta-analysis. J Clin Pharmacol. 2013;53(3):345–51.CrossRefPubMed Zhang T, Shen L, Hu L, He B. Optimal duration of dual-antiplatelet therapy following drug-eluting stent implantation: a meta-analysis. J Clin Pharmacol. 2013;53(3):345–51.CrossRefPubMed
Metadata
Title
Extremely late (7 years) paclitaxel-eluting stent thrombosis
Authors
J. A. Linares Vicente
J. R. Ruiz Arroyo
B. Simó Sánchez
A. Lukic
P. Revilla Martí
Publication date
01-04-2015
Publisher
Springer Japan
Published in
Cardiovascular Intervention and Therapeutics / Issue 2/2015
Print ISSN: 1868-4300
Electronic ISSN: 1868-4297
DOI
https://doi.org/10.1007/s12928-014-0270-8

Other articles of this Issue 2/2015

Cardiovascular Intervention and Therapeutics 2/2015 Go to the issue